Japan first country to approve VAL001 patent
Japan has as the first country in the world approved Respiratorius patent application VAL001, "A Pharmaceutical Composition Comprising a HDAC inhibitor and a Steroid and the Use thereof."The patent gives Respiratorius market exclusivity in Japan for a combination of HDAC inhibitors and steroid pre-treatment before chemotherapy (R-CHOP) in the treatment of diffuse large B-cell lymphoma (DLBCL), a lymphoma that annually affects about 60,000 people in the US and Europe. DLBCL is the most common type of Non-Hodgkin's lymphoma, which comprises 30% of the affected patients in the EU and the US,